A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs GSK 2696275 (Primary)
- Indications Wiskott-Aldrich syndrome
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- Acronyms TIGET-WAS
- 22 Apr 2017 Planned End Date changed from 1 Apr 2023 to 31 Mar 2023.
- 05 Dec 2015 According to a media release, data from this study will be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition 2015.
- 10 Jun 2015 New trial record